(Q34558562)

3 August 2017

1 reference

title

Cellular and clinical pharmacology of fludarabine (English)

1 reference

3 August 2017

1 reference

2

William Plunkett

1 reference

3 August 2017

Varsha Gandhi

1

1 reference

3 August 2017

1 January 2002

1 reference

Clinical Pharmacokinetics

3 August 2017

1 reference

3 August 2017

41

1 reference

3 August 2017

93-103

1 reference

3 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200241020-00002

3 August 2017

0 references

cites work

Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.

1 reference

12 December 2020

2-Fluoroadenosine 3':5'-monophosphate. A metabolite of 2-fluoroadenosine in mouse cytotoxic lymphocytes

1 reference

12 December 2020

Gene deletion, a mechanism of induced mutation by arabinosyl nucleosides

1 reference

12 December 2020

Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia

1 reference

12 December 2020

Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent

1 reference

12 December 2020

In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells

1 reference

12 December 2020

Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies

1 reference

12 December 2020

Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia

1 reference

12 December 2020

A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.

1 reference

12 December 2020

Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo

1 reference

12 December 2020

Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism

1 reference

12 December 2020

A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids

1 reference

12 December 2020

Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388

1 reference

12 December 2020

Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs

1 reference

12 December 2020

High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells

1 reference

12 December 2020

Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group

1 reference

12 December 2020

Biologic activity of 9-β-d-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-d-arabinofuranosyladenine

1 reference

12 December 2020

Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients

1 reference

12 December 2020

Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells

1 reference

12 December 2020

Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells

1 reference

12 December 2020

Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy

1 reference

12 December 2020

Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.

1 reference

12 December 2020

9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma

1 reference

12 December 2020

Nucleotide specificity of human deoxycytidine kinase

1 reference

12 December 2020

Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis

1 reference

12 December 2020

Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity

1 reference

12 December 2020

Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule

1 reference

12 December 2020

Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate

1 reference

12 December 2020

Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase.

1 reference

12 December 2020

Differences in metabolism and cytotoxicity between 9-beta-D arabinofuranosyladenine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts

1 reference

12 December 2020

Metabolism and action of purine nucleoside analogs

1 reference

12 December 2020

DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis

1 reference

12 December 2020

Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.

1 reference

12 December 2020

Some comparative studies of calf and chicken adenosine deaminase

1 reference

12 December 2020

Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.

1 reference

12 December 2020

Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy

1 reference

12 December 2020

Nucleosides of 2-Fluoroadenine

1 reference

12 December 2020

Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite

1 reference

12 December 2020

Specificity of adenosine deaminase toward adenosine and 2'-deoxyadenosine analogues

1 reference

12 December 2020

Primer RNA chain termination induced by 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate. A mechanism of DNA synthesis inhibition

1 reference

12 December 2020

Pharmacokinetic study of fludarabine phosphate (NSC 312887)

1 reference

12 December 2020

Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity

1 reference

12 December 2020

Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c

1 reference

12 December 2020

Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences

1 reference

12 December 2020

Incorporation of nucleosides into the nucleotide pools of human erythrocytes. Adenosine and its analogs

1 reference

12 December 2020

Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine

1 reference

12 December 2020

Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event

1 reference

12 December 2020

Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway

1 reference

12 December 2020

Inhibition of the 3' --> 5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA

1 reference

12 December 2020

Structure-activity relationships and cross-resistance observed on evaluation of a series of purine analogs against experimental neoplasms.

1 reference

12 December 2020

Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule

1 reference

12 December 2020

Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy

1 reference

12 December 2020

Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions

1 reference

12 December 2020

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

12 December 2020

Incorporation of 9-beta-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA

1 reference

12 December 2020

Metabolism and action of fludarabine phosphate

1 reference

12 December 2020

Eukaryotic DNA ligases

1 reference

12 December 2020

Inhibition of fludarabine metabolism by arabinosylcytosine during therapy

1 reference

12 December 2020

Metabolism of 2-fluoroadenosine by Ehrlich ascites cells

1 reference

12 December 2020

Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy

1 reference

12 December 2020

10.2165/00003088-200241020-00002

Identifiers

DOI

1 reference

PubMed ID

11888330

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

11888330